tor (EGF) family of ligands contains several members that are produced as transmembrane proteins and undergo cleavage and release of their extracellular ligand-binding domain in response to a variety of stimuli. This process is responsible for growth factorlike responses to stimuli, e.g., hypertonic shock, not previously considered to activate traditional growth factor receptor signaling pathways (1) . The activation of EGF-receptor family members (erbBs) by some Gprotein-coupled receptor ligands has been shown to be mediated by metalloproteinase (MP)-induced cleavage and release of heparin-binding EGF (2) . The importance of this mechanism in the regulation of growth factor signaling is emphasized by the observation that transgenic elimination of the MPs responsible for cleavage of these factors results in multiple developmental abnormalities that mimic loss of the growth factors themselves (3) (4) (5) .
Cytokines are important modulators of vascular function. The role of certain cytokines such as interleukin-6 (IL-6) in inducing vascular remodeling and angiogenesis in the setting of inflammation has been established in several models, including human inflammatory diseases (6, 7) . Other cytokines, such as interleukin-1␤ (IL-1␤), have more pleiotropic properties in regulating vascular structure and function but also promote vascular cell proliferation in in vivo models (8 -10) . The mechanisms by which these cytokines promote growth factor-like responses in the vasculature may include cross talk between the Jak-STAT and MAPK signaling pathways at multiple levels.
We hypothesized that one potential mechanism by which cytokines could elicit growth factor-like responses in vascular endothelial cells (ECs) could be by promoting release of preformed pools of the EGF family ligand neuregulin-1 (NRG). Rat cardiac microvascular ECs express NRG in its promembrane or transmembrane form and release this protein in response to H 2 O 2 (11) . Here, we demonstrate that human ECs also express pro-NRG that is released in response to phorbol esters [phorbol myristate acetate (PMA)] or selected inflammatory cytokines. The release of NRG in response to these cytokines is blocked by inhibitors of MP activity. The ADAM (a disintegrin and metalloproteinase) subfamily of MPs has been shown to participate in regulated ectodomain cleavage of a number of transmembrane proforms of growth factors, including members of the EGF family (12) . Inhibition or decreased expression of one specific ADAM, TNF-␣-converting enzyme (TACE), leads to decreased release of NRG in response to cytokines but not to PMA, suggesting that multiple MPs may mediate NRG release in response to different stimuli. The same cytokines that cause NRG cleavage from ECs can activate ERK (p44/42 MAPK, a known downstream signaling pathway for erbB receptors), and this effect is also blocked by inhibition of TACE. Cytokine-induced in vitro angiogenesis (Matrigel cord formation) by ECs was also significantly inhibited by MP inhibitors or by inhibitors of erbB kinase activity. In addition, anti-NRGneutralizing antibodies also significantly inhibit cord formation in response to these cytokines, supporting the idea that NRG is a key mediator of this endothelial cytokine response. These findings suggest that one mechanism by which inflammatory cytokines may induce angiogenic responses in ECs is by MPmediated release of NRG and autocrine/paracrine stimulation of erbB signaling.
MATERIALS AND METHODS

Materials
Recombinant cytokines and growth factors were obtained from the following sources: IFN-␥, IL-6, and IL-1␤ were purchased from Roche Pharmaceuticals (Indianapolis, IN, USA); TNF-␣ was from Endogen (Woburn, MA, USA); and NRG␣ and NRG␤ were from Oncogene Research Products (La Jolla, CA, USA) or Sigma-Aldrich (St. Louis, MO, USA). The MP inhibitors (MMPiII, MMPiIII), AG18, AG825, and TAPI-1 were all purchased from Calbiochem (San Diego, CA, USA). Unless otherwise noted, all other chemicals were purchased from Sigma-Aldrich.
Cell isolation and culture
Human umbilical vein endothelial cells (HUVECs) were isolated from pooled donors and maintained as described previously (13, 14) . This investigation conforms with the principles outlined in the Declaration of Helsinki, 1997. EAhy926 cells were a generous gift of Dr. C. J. Edgell (University of North Carolina, Chapel Hill, NC, USA; ref. 15) and were maintained in DMEM with 10% FBS, 5 mM hypoxanthine, 0.8 mM thymidine, and 20 M aminopterin. Cells were plated at 90% confluence and serum starved in DMEM with 0.1-0.5% fatty acid-free BSA before cytokine or NRG stimulation.
Immunoprecipitation and immunoblotting
Cell monolayers were treated as described in the figure legends. At the end of the treatment period, cell medium was collected, and monolayers were washed with cold PBS and lysed in RIPA buffer [PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitors (Complete Mini, EDTA-free cocktail; Roche)]. Protein concentrations in cell lysates were measured using the Bio-Rad protein assay (a modified Bradford assay; Bio-Rad, Richmond, CA, USA) to equalize loading for all blots. For analysis of released NRG, cell culture medium was collected and dialyzed overnight in a membrane (molecular weight cutoff, 3500; Spectrum Laboratories, Rancho Dominguez, CA, USA) against PBS. Subsequently, 1 g of anti-NRG antibody (7D5; Lab Vision/ NeoMarkers, Fremont, CA, USA) was added to the dialyzed culture medium and was retrieved with protein A/G plus Sepharose (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoblotting for NRG was performed using sc-348 (Santa Cruz Biotechnology) to detect cell-associated NRG and Ab-1 (Oncogene Research Products or R&D Systems, Minneapolis, MN, USA) to detect released NRG from culture medium immunoprecipitations. Immunoblotting for phospho-and total ERK was performed using antibodies from Cell Signaling (Beverly, MA, USA). Actin and ␤-tubulin antibodies (Santa Cruz Biotechnology) were used for loading controls. Immunoblots were probed with horseradish peroxidase-coupled species-specific secondary antibodies (Santa Cruz Biotechnology) and visualized using enhanced chemiluminescence (Perkin-Elmer, Wellesley, MA, USA).
siRNA transfections
The TACE-targeted and control scrambled siRNAs were purchased from Ambion (Austin, TX, USA). EAhy926 cells were seeded into 6-well plates 1 d prior to transfection. Monolayers of cells (50 -60% confluent) were transfected with siRNA in Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer's recommendation. At the end of a 4-h incubation, the medium was replaced with fresh growth medium. Cells were then incubated for an additional 48 h prior to additional treatments and harvesting for immunoblotting. TACE expression was evaluated by immunoblotting with an anti-TACE antibody (Santa Cruz Biotechnology).
Matrigel cord formation assays
Growth factor reduced Matrigel (175 l, BD Biosciences, San Jose, CA, USA) was placed in 48-well plates and allowed to polymerize at 37°C. Early passage (Ͻ3) HUVEC cell suspensions containing NRG, IFN-␥, IL-6, MP inhibitors, or AG compounds as described in the figure legends were plated at a density of 2.5 ϫ 10 4 in medium 199 containing 10% FBS overnight. For experiments using neutralizing antibodies, cells were preincubated with antibody cocktail containing anti-NRG1-␣ (goat, 10 g/ml; R&D Systems) and anti-NRG1-␤1 (goat, 5 g/ml; R&D Systems) or control preimmune serum (goat, 15 g/ml; Abcam, Cambridge, MA, USA) for 15 min at 37°C and then plated overnight on Matrigel (as above) with IL-6 (100 U/ml, Roche) or IFN-␥ (50 U/ml, Roche). Cords were quantitated manually (using phase contrast microscopy and National Institutes of Health Image J software) in 6 -12 fields from 3 or 4 replicate wells per experimental treatment. GraphPad Prism 3 software (GraphPad, San Diego, CA, USA) was used to perform 1-way ANOVA with the Tukey post hoc analysis for comparisons among paired groups.
RESULTS
Effect of cytokines on neuregulin cleavage and secretion in human vascular ECs
We hypothesized that growth factor-like responses of ECs to some cytokines might be explained by cleavage of transmembrane NRG with subsequent elaboration of the extracellular EGF-containing domain and autocrine or paracrine activation. We first evaluated whether stimulation of ECs with candidate cytokines resulted in NRG cleavage and release into the cell medium. Figure 1 shows that both primary HUVECs (Fig. 1B) and the immortalized HUVECderived EAhy926 cell line (Fig. 1A ) express abundant full-length (or pro-) NRG (indicated by arrowhead, and labeled as full-length or cell-associated NRG in this and subsequent figures). This full-length NRG migrates at ϳ130 kDa, and additional lowermolecular-weight bands are often seen, as described by other investigators (16) . These bands have been proposed to represent splice variants of NRG or intracellular processed fragments occurring after extracellular domain cleavage, as the antibody used in these assays binds to the c-terminal (intracellular) region of the molecule. Stimulation with IL-6 or IFN-␥ resulted in loss of the full-length NRG from the cell. A decrease in the amount of full-length NRG was seen as early as 1 h of cytokine stimulation in both cell types, and much of the full-length NRG was cleaved by 4 -8 h. Interestingly, despite the continued presence of IFN-␥ or IL-6 in the 12-h cell stimulation assays, the ECs were able to reexpress basal levels of full-length NRG. Thus, the mechanism by which NRG is cleaved in response to these cytokines may be only transiently activated, and cell synthesis of NRG may also be activated in response to cytokine stimulation.
Next, we wanted to test how rapidly the cleavage and release of NRG occurs after cytokine stimulation. As full-length NRG is relatively abundant in HUVECs and EAhy926 cells under our culture conditions, small decreases in cell-associated NRG can be somewhat difficult to measure. Therefore, we used immunoprecipitation of culture medium to detect NRG elaborated as early as 10 min and up to 240 min after IFN-␥ or IL-6 stimulation. As shown in Fig. 2 , stimulation with IFN-␥ or IL-6 led to rapid accumulation of NRG in the culture medium that was detectable as early as 10 min. This suggests that the mechanism of cytokine-induced release involves activation of preformed proteases rather than increased expression of the proteases responsible for NRG cleavage. It is important to note that the amount of NRG found in the medium at any given time point after release for the cell surface may also be affected by factors such as protein stability or binding of NRG to cell surface receptors, with subsequent internalization and intracellular degradation of NRG. Interestingly, the peak of loss of cell-associated full-length NRG and accumulation of NRG in the cell medium was delayed in response to IL-6 when compared to IFN-␥, suggesting that there may be some differences in the kinetics of cleavage or turnover of NRG in response to these cytokines.
Multiple other cytokines that are well-described activators of vascular ECs were tested in this assay. As shown in Fig. 3A , there was no cleavage of NRG from ECs in response to IL-1␤ given at concentrations from 4 to 400 U/ml. Under these conditions, IL-6 causes efficient cleavage at 40 -100 U/ml and IFN-␥, at 50 U/ml (Fig.  3A, B) . TNF-␣ can activate NRG cleavage efficiently as early as 1 h after addition (Fig. 3B) . Interestingly, TNF-␣ appears to activate NRG cleavage more efficiently at the lower dose tested, suggesting a reversedose response.
Effect of PKC activation or calcium flux on neuregulin cleavage and secretion in human vascular ECs
PKC activation has previously been reported to activate NRG cleavage from Chinese hamster ovary cells (17) . On the basis of this observation, we tested whether PMA can activate cleavage of NRG in ECs. Figure 3C shows that PMA can induce cleavage of NRG as early as 10 -30 min. Extracellular Ca 2ϩ influx has also been shown to activate cleavage of another transmembrane member of the EGF family, HB-EGF, via a PKC-independent mechanism (18). We found that the calcium ionophore, ionomycin, can also rapidly induce NRG cleavage in ECs (Fig. 3C) . These findings suggest that several stimuli whose downstream signaling pathways are potentially divergent can activate a common mechanism for cleavage and release of the extracellular domain of NRG. Next, we wanted to elucidate what this common mechanism is in ECs.
Effect of inhibiting MP activity on NRG cleavage in response to cytokines or PMA
A variety of MPs have been shown to be involved in ectodomain cleavage of transmembrane proteins. To test whether MP activity is required for IFN-␥-induced NRG cleavage, we used 2 broad-spectrum MP inhibi- Fig. 4C) or longer (4.5 h,  Fig. 4D ) exposure to these MP inhibitors. Figure 4A shows that MMPiII dose-dependently blocks cleavage and release of NRG in response to IFN-␥. At a dose of 5 nM, this inhibitor had little effect on NRG cleavage, whereas at 100 nM, IFN-induced cleavage was almost entirely abolished. MMPiIII effectively blocked cleavage at a slightly lower dose. Interestingly, at similar doses, these inhibitors do not block NRG cleavage in response to PMA. This may suggest that the mechanisms or MPs responsible for PKC-induced NRG cleavage are distinct from those responsible for IFN-␥-induced cleavage.
Cleavage of proforms of NRG in response to PMA has been shown to depend on the protease activity of TACE, a member of the ADAM subfamily of MPs. To test whether TACE activity is responsible for pro-NRG cleavage in ECs, we pretreated cells with an inhibitor of TACE (TAPI-1) prior to stimulation with IFN-␥, IL-6, or PMA. There was no significant change in basal levels of cell-associated NRG for up to 4.5 h of treatment with TAPI (Fig. 4C, D) . At the lowest concentration used (10 M), TAPI was able to inhibit NRG cleavage in response to IFN-␥ (Fig. 5A ) or IL-6 (Fig. 5C ). Next, we used siRNA directed against TACE to confirm its role in IFN-␥ and IL-6 activation of ECs leads to rapid release of NRG into medium. Serum-starved, confluent monolayers of ECs were treated with IFN-␥ (50 U/ml) (A) or IL-6 (100 U/ml) (B) for the indicated times, and NRG was immunoprecipitated from the culture medium for immunoblotting. For each cytokine, a representative immunoblot (top panel) and summary plot of pixel densitometry (bottom panel) from 3 or 4 independent experiments is shown. For each blot, samples were normalized to the time 0 control, which was given a value of 1. Thus, the y-axis represents mean Ϯ se fold increase over control medium.
NRG cleavage from ECs. Figure 5B shows that in the absence of any additional treatment, there is significantly more full-length NRG present in ECs when TACE expression is decreased for the Ͼ48 h used to achieve effective silencing of TACE expression, suggesting that TACE activity may be responsible for slow basal release of NRG under our cell culture conditions. Of note, this differs from the findings with inhibition of TAPI or MMPi for shorter periods of time (up to 4.5 h), where no detectable difference was seen (Fig. 4C, D) . IFN-␥ did not induce significant NRG cleavage in the presence of TACE-directed siRNA, similar to the findings in the presence of TAPI (Fig. 5B) . However, either in the presence of TAPI (Fig. 5A ) or under conditions of significantly reduced TACE expression (Fig. 5B) , PMA could still induce NRG cleavage, suggesting that TACE is not required for this effect in ECs.
Effects of MP or erbB kinase inhibition on cytokine-induced ERK activation and in vitro cord formation
We have previously reported that HUVECs express erbB2, 3, and 4 (14) . We next tested whether activation of ECs by NRG would result in downstream signaling, specifically activation of ERKs (p44/42 MAPK). NRGactivated ERK in a time (Fig. 6A) and dose-dependent (Fig. 6B ) manner in HUVECs (Fig. 6A ) and EAhy926 cells (Fig. 6B) . Similarly, IL-6 and IFN-␥ stimulation of ECs resulted in ERK activation with slightly delayed kinetics compared with NRG (Fig. 6C) . Activation of ERK in response to these cytokines was largely abrogated in the presence of TAPI. Taken together, these data support the idea that IFN-␥ and IL-6 share the ability to activate ERK signaling with NRG in ECs and that TACE inhibition blocks the ability of these cytokines to promote NRG release and activate ERK.
We have also previously shown that NRG is proangiogenic, both in vitro, using a collagen gel cord-formation assay with HUVECs, and in vivo, in a rat corneal angiogenesis assay (14) . On the basis of these observations, we tested whether cytokine-induced NRG cleavage could mimic the functional consequences of direct NRG stimulation of ECs. We found that IL-6 activated ECs to form cordlike structures in collagen matrix assays (Fig. 7A) . In addition, IL-6-stimulated cord formation is significantly decreased in the presence of MMPiIII. Notably, cord formation in response to purified NRG1␣ was not affected by the addition of MMPiIII, suggesting that the effect of this MMPi does not simply block the ability of ECs to form cords during stimulation of the NRG signaling pathway. The addition of AG825, a broad-spectrum erbB kinase inhibitor, or AG18, a more selective inhibitor of erbB2, each blocked cord formation in response to either IL-6 or NRG. This suggests that erbB signaling, specifically through erbB2, is important in mediating cord formation in response to these stimuli. To further test whether NRG is responsible for the effects of IL-6 or IFN-␥ on EC cord formation, we pretreated ECs with anti-NRG-neutralizing antibodies (directed against both ␣ and ␤ isoforms) and then exposed them to these cytokines in similar collagen matrix assays. As shown in Fig. 7B , IFN-␥ can also induce EC cord formation in this assay. Cord formation in response to either IL-6 or IFN-␥ is significantly inhibited in the presence of anti-NRG-neutralizing antibodies, but not in the presence of control Ig (preimmune goat serum). Taken together, these data support the idea that cytokine-induced NRG cleavage (via MMP activity) and release can activate signaling pathways in ECs and induce phenotypic changes in these cells.
DISCUSSION
We found that cultured ECs, as well as human cardiac ECs (data not shown), abundantly express NRG. This NRG is present in its proform and undergoes regulated cleavage from the cell and release into the medium in response to certain inflammatory cytokines, as well as PMA and the Ca 2ϩ ionophore, ionomycin. This effect occurs rapidly, with a time course similar to that seen in response to PMA or hypertonic stress in other cell types, where cleavage is easily detected within 20 min of activation (19, 20) . Most NRGs are synthesized as transmembrane precursors that undergo proteolytic processing largely at the cell surface (21) . Animals carrying a mutation in NRG that decreases its ability to be proteolytically processed die in utero with cardiovascular developmental abnormalities that closely mimic full deletion of the NRG-1 gene (22, 23) , suggesting that regulated proteolytic processing of NRG plays a critical role in its biological function. Several stimuli have been shown to promote NRG cleavage, including phorbol esters, hypertonic agents (sorbitol), ultraviolet irradiation, Ca 2ϩ ionophores, FBS, and H 2 O 2 (1, 11, 17, 19, 21) . Mechanisms by which this wide variety of stimuli activates NRG cleavage involve multiple signaling pathways, including PKC isoenzymes (17, 20) .
Cytokine modulation of protease activity has been described in several other cell and tissue types. IFN-␥ and TNF-␣ increase ␥-secretase activity with subsequent increases in proteolytic processing of amyloid precursor protein and Notch in human embryonic kidney cells (24) . Both IFN-␥ and TNF-␣ have been shown to increase gelatinase activity of MMP-2 and MMP-9 in neural precursor cells, enhancing neuronal repair during inflammatory injury (25) . Stimulation of murine ECs with either IL-1␤ or TNF-␣ increases VCAM-1 cleavage and release of its extracellular domain, and this effect requires TACE (ADAM-17) activity (26) . Interestingly, we did not find activation of NRG cleavage in response to IL-1␤, suggesting that HUVECs may respond differently than the immortalized murine line used in these studies. The mechanisms by which cytokines modulate MP activity include transcriptional upregulation of the protease itself and down-regulation of inhibitors. MMP-9 activation by TNF-␣ is mediated by transcriptional MMP-9 up-regulation in glioma cells, whereas down-regulation of TIMP-1 is responsible for increased MMP-9 activation in human salivary gland (27, 28) . Our data show that there is an early release of NRG from the cell surface based on immunoprecipitation of cell culture medium (Fig. 2) , as well as more prolonged NRG cleavage with a peak loss of cellassociated NRG occurring at 1-8 h (Fig. 1) . These results suggest both rapid enzymatic activation and transcriptional regulation of MP activity after cytokine stimulation may occur. The rapid accumulation of NRG in the cell medium relative to its disappearance from the cell surface may also be due to alterations in NRG protein turnover in this system. Further work will be needed to discern which of these mechanisms is responsible for cytokine activation of NRG cleavage and accumulation of this product in extracellular pools. There appears to be more than one specific MP involved in the process of EC NRG release, since we found that the broad-spectrum MP inhibitors and or more specific inhibition of TACE (using TAPI or siRNA) blocked NRG release in response to cytokines but not during PMA stimulation. In contrast, fibroblasts from TACE-knockout mice appear to be unable to cleave NRG in response to PMA (19) . In these experiments, investigators transfected an expression construct for tagged proNRG␣2c into either 293 cells or TACE Ϫ/Ϫ fibroblasts. The differences between these data and ours with respect to PMA stimulation might be explained by either cell type or species differences. An alternative explanation is that the specific NRG isoform used in the murine fibroblast experiments (NRG␣2c) is preferentially cleaved by TACE in response to PMA, and this may not be the primary or only isoform in human ECs. In our experiments, we could detect both endogenous ␣ and ␤ isoforms of NRG based on the specificity of the antibodies used for immunoprecipitation and immunoblotting.
We have also recently found that human ECs express RNA for the MP Kuzbanian (ADAM 10, data not shown), which has been shown to participate in PKCregulated cleavage of other proteins (29) . Transfection of murine L929 fibroblasts with a meltrin ␤ (ADAM 19) expression construct resulted in increased basal cleavage and release of NRG␤ (30) . However, these investigators reported that transfection of the cells with a dominant-negative meltrin ␤ construct did not block the ability of these cells to release NRG in response to PMA, further supporting the idea that multiple MPs may be capable of cleaving NRG in different cell types and in response to different stimuli. The link between inflammation, MP activation, and angiogenesis is important in human diseases (e.g., arthritis, atherogenesis), in which these processes contribute to the pathogenesis of the disease (e.g., joint destruction, intimal neovascularization, and plaque destabilization). We have previously shown that NRG promotes in vivo angiogenesis (14) . Using Matrigel assays, we have found that IL-6, IFN-␥, and NRG promote EC cord formation. IL-6 and IFN-␥ induced cord formation is dependent on MP activity, whereas cord formation induced by the extracellular (mature or cleaved) domain of NRG is not. By contrast, cord formation in response to both these cytokines and NRG was decreased by erbB kinase inhibition, demonstrating the importance of activation of these receptors for this response. The importance of NRG for EC cord formation in response to these cytokines is further demonstrated by the finding that neutralizing antibodies directed against NRG block cord formation. On the basis of these data, we propose a model in which IL-6 (or IFN-␥) increases MP (including TACE) activity, release of NRG, activation of erbB receptor signaling (including ERK activation), and enhanced in vitro angiogenesis. This may represent a novel mechanism for cytokineinduced angiogenesis, though this hypothesis will still need to be tested in vivo. Other mechanisms by which cytokines promote angiogenesis include increased production and secretion of vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (31, 32) . Both IL-6 (32) and IFN-␥ (in a cell type-dependent fashion; ref. 33 ) increase VEGF expression, while IL-1␤ appears to decrease angiopoietin-1 expression in ECs (8) and can elicit angiogenesis via a COX-2-dependent pathway that is not mediated by VEGF receptor signaling (9) . We also found a difference in the effects of IL-6, IFN-␥, and IL-1␤ on NRG release, which further highlights the different mechanisms responsible for the proangiogenic activities of these cytokines.
In summary, we have shown that selected inflammatory cytokines promote NRG release, which might play an important role in the angiogenic potential of these proteins. Elevated serum concentrations of many inflammatory cytokines have been found in patients with heart failure, in whom this finding is associated with a poor prognosis. The mechanisms by which these cytokines promote (or prevent) the progression of heart failure may include activation of MPs leading to adverse remodeling of cardiac matrix components. Therefore, our data regarding the possible role of MPs in NRG release and angiogenesis have important implications for strategies aimed at modulating cardiac remodeling via MP inhibition. Therapeutic agents that affect not only the function of matrix degradation by MPs, but also their regulation of growth factor release could have a negative impact on both physiological (beneficial) and pathological angiogenesis in the setting of cytokine stimulation. This information may help us design strategies allowing the development of selective MP inhibitors that avoid potential adverse angiogenic effects.
